Collegium Pharmaceutical (NASDAQ:COLL) Price Target Raised to $56.00

Collegium Pharmaceutical (NASDAQ:COLL) had its price objective boosted by equities researchers at Needham & Company LLC from $48.00 to $56.00 in a research report issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Needham & Company LLC’s target price indicates a potential upside of 14.80% from the company’s current price.

A number of other brokerages have also issued reports on COLL. HC Wainwright reissued a “buy” rating and issued a $60.00 price target (up previously from $46.00) on shares of Collegium Pharmaceutical in a report on Friday. Wall Street Zen raised Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Barclays began coverage on Collegium Pharmaceutical in a research report on Monday, December 8th. They set an “overweight” rating and a $58.00 price target for the company. Weiss Ratings reiterated a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research report on Monday, December 29th. Finally, Zacks Research cut Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Five analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.20.

Collegium Pharmaceutical Price Performance

COLL opened at $48.78 on Thursday. The stock’s 50 day simple moving average is $46.04 and its 200 day simple moving average is $38.38. The company has a debt-to-equity ratio of 2.71, a current ratio of 1.36 and a quick ratio of 1.27. Collegium Pharmaceutical has a 1 year low of $23.23 and a 1 year high of $50.79. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of 30.30 and a beta of 0.60.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 earnings per share for the quarter. Collegium Pharmaceutical had a return on equity of 102.03% and a net margin of 7.72%.The firm had revenue of $135.55 million during the quarter. As a group, analysts predict that Collegium Pharmaceutical will post 5.62 earnings per share for the current year.

Insider Transactions at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, Director Rita J. Balice-Gordon sold 3,650 shares of the firm’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $47.03, for a total transaction of $171,659.50. Following the completion of the transaction, the director owned 52,629 shares of the company’s stock, valued at approximately $2,475,141.87. This trade represents a 6.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Colleen Tupper sold 30,000 shares of the company’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $40.53, for a total transaction of $1,215,900.00. Following the completion of the sale, the chief financial officer directly owned 126,667 shares in the company, valued at $5,133,813.51. This represents a 19.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 51,250 shares of company stock valued at $2,235,352. Corporate insiders own 2.51% of the company’s stock.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of hedge funds and other institutional investors have recently bought and sold shares of COLL. Federated Hermes Inc. grew its stake in shares of Collegium Pharmaceutical by 67.0% in the 3rd quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock worth $31,000 after buying an additional 350 shares during the last quarter. CWM LLC raised its position in shares of Collegium Pharmaceutical by 453.9% in the 2nd quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 1,153 shares during the last quarter. Hantz Financial Services Inc. boosted its stake in Collegium Pharmaceutical by 137.7% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company’s stock worth $60,000 after purchasing an additional 993 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in Collegium Pharmaceutical by 744.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock worth $73,000 after purchasing an additional 2,190 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in Collegium Pharmaceutical by 368.9% during the 2nd quarter. GAMMA Investing LLC now owns 2,757 shares of the specialty pharmaceutical company’s stock valued at $82,000 after purchasing an additional 2,169 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.